ArticleWorld journal of clinical cases2025
High-resolution optical coherence tomography for screening ocular surface tumors: Historical markers and future directions.
Article in World journal of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High-Resolution Anterior Segment Optical Coherence Tomography Characteristics of Conjunctival Tumors.Journal of clinical practice and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-resolution optical coherence tomography (HR-OCT) has become an essential instrument in the screening and diagnosis of ocular surface neoplasms. Research demonstrates that HR-OCT possesses a diagnostic sensitivity ranging from 85% to 90% for ocular surface squamous neoplasia (OSSN). The connections between HR-OCT features and histological findings have consistently shown robustness, hence increasing the reliability of clinical diagnosis.
aimTo examine the existing HR-OCT indicators employed in the identification of common non-benign ocular surface tumors, namely, basal cell carcinoma, OSSN, and melanocytic conjunctival lesions, and to assess their diagnostic efficacy, benefits, and prospective developments.
methodsA thorough literature review was performed to assess the published research on HR-OCT in the diagnosis of ocular surface cancers. Significant attention was given to research that compares HR-OCT characteristics with histopathologic validation, as well as on publications addressing the integration of emerging technologies and artificial intelligence in ocular oncology imaging.
resultsHR-OCT exhibits elevated diagnostic sensitivity (85%-90%) for identifying OSSN and presents distinct imaging patterns that align closely with histology results. This approach has substantial clinical advantages due to its non-invasive characteristics, improved axial resolution, and real-time imaging capabilities. HR-OCT has demonstrated potential in assessing various lesions, including basal cell carcinoma and melanocytic conjunctival malignancies.
conclusionHR-OCT assumes an increasingly vital role in the early identification and clinical management of ocular surface malignancies. With advancements in imaging technology and the integration of artificial intelligence, HR-OCT is anticipated to enhance individualized diagnosis and treatment planning in ocular oncology, hence improving patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.